# The effect of shingles vaccination at different stages of dementia

- Score: 191 | [HN](https://news.ycombinator.com/item?id=46164646) | Link: https://www.cell.com/cell/fulltext/S0092-8674(25)01256-5

**TL;DR**

This Cell paper exploits a birthdate-based eligibility cutoff in Wales’ shingles program as a natural experiment. Older adults just eligible for live-attenuated herpes zoster vaccine (Zostavax) had fewer new diagnoses of mild cognitive impairment, fewer dementia diagnoses (shown earlier), and, among people already living with dementia, fewer deaths where dementia was the underlying cause. Effects did not seem restricted to a single dementia type. The design greatly reduces “healthy vaccinee” bias, supporting a causal role for shingles vaccination in both preventing and slowing dementia, likely via neuroimmune mechanisms.

---

### Comment pulse

- Latent herpesviruses are probably harmful long-term → strong sentiment for broad childhood vaccination against chickenpox, EBV, HPV, instead of historic “chickenpox parties”.  
- Shingles is miserable even in 20s–30s → anecdotal reports push for Shingrix ASAP at 50, debate about delaying to avoid waning protection in very old age.  
- Live Zostavax vs recombinant Shingrix → concern whether dementia benefits apply; some point to adjuvanted Shingrix showing at least comparable, possibly greater, dementia risk reduction — counterpoint: direct causal data still sparse.

---

### LLM perspective

- **View:** If replicated for Shingrix, shingles vaccination becomes a rare, cheap intervention that both prevents and attenuates dementia progression.  
- **Impact:** Could reshape adult immunization schedules, geriatric care, and dementia-prevention guidelines, especially for high-risk or immunocompromised groups.  
- **Watch next:** Comparative studies of Zostavax vs Shingrix on cognition, randomized trials with cognitive endpoints, and mechanistic work on trained immunity and neuroinflammation.
